CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.

Headline results from a REDEFINE-2 late-stage trial released earlier this month showed that Novo's next-generation CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15. ...

Results from REDEFINE 2, a phase 3 study that evaluated the efficacy and safety of CagriSema plus lifestyle interventions in adults with obesity and type 2 diabetes (T2D), were also simultaneously ...

The REDEFINE 2 trial enrolled 1206 adults with overweight/obesity and type 2 diabetes, 904 of whom were randomized to CagriSema and 302 to placebo. The mean age was 56, half were men, two-thirds ...

The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group (estimated difference [95% CI] -20.4 [-21.1 to -19.7 ...

The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group (estimated difference [95% CI] -20.4 [-21.1 to -19.7 ...

The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group (estimated difference [95% CI] -20.4 [-21.1 to -19.7 ...

In REDEFINE 1, participants lost an average of 20.4% of their body weight with CagriSema at week 68, compared to 11.5% with cagrilintide, 14.9% with semaglutide, and 3% with placebo.